Pariet: Advanced Acid Control for Gastric Health
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.48 | $43.03 (0%) | 🛒 Add to cart |
| 120 | $0.45 | $57.37 $54.03 (6%) | 🛒 Add to cart |
| 180 | $0.43 | $86.05 $77.05 (10%) | 🛒 Add to cart |
| 270 | $0.41 | $129.08 $111.07 (14%) | 🛒 Add to cart |
| 360 | $0.40
Best per pill | $172.10 $144.09 (16%) | 🛒 Add to cart |
Pariet (rabeprazole sodium) is a proton pump inhibitor (PPI) designed for the effective management of acid-related gastrointestinal disorders. As a next-generation therapeutic agent, it offers potent and prolonged suppression of gastric acid secretion by targeting the H+/K+ ATPase enzyme system in the parietal cells of the stomach. Clinically, it is indicated for a range of conditions including gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger-Ellison syndrome. Its rapid onset of action and consistent pharmacokinetic profile make it a preferred choice among gastroenterologists and primary care providers seeking reliable symptom relief and mucosal healing for patients.
Features
- Contains rabeprazole sodium as the active ingredient
- Available in delayed-release tablet formulations (typically 10 mg and 20 mg)
- Designed for oral administration with enteric coating to ensure drug stability in the stomach
- Exhibits high bioavailability and rapid absorption
- Demonstrated efficacy in 24-hour acid suppression
- Suitable for short-term and maintenance therapy
Benefits
- Provides rapid and sustained relief from heartburn, regurgitation, and other GERD symptoms
- Promotes healing of erosive esophagitis and reduces risk of recurrence
- Effective in eradicating Helicobacter pylori when used in combination therapy
- Helps prevent NSAID-induced gastric ulcers in at-risk patients
- Supports overall improvement in quality of life by managing chronic acid-related symptoms
- Offers flexible dosing options tailored to individual therapeutic needs
Common use
Pariet is commonly prescribed for the treatment of conditions where reduction of gastric acid secretion is beneficial. This includes healing and maintenance of erosive GERD, treatment of duodenal and gastric ulcers, and management of hypersecretory conditions such as Zollinger-Ellison syndrome. It is also widely used as part of combination therapy regimens for the eradication of H. pylori infection, alongside antibiotics like amoxicillin and clarithromycin. In clinical practice, it may be used for the prevention of ulcers in patients requiring long-term NSAID therapy.
Dosage and direction
The dosage of Pariet should be individualized based on the condition being treated and patient response. For most adults with GERD, the recommended dose is 20 mg once daily for 4 to 8 weeks. For H. pylori eradication, a dose of 20 mg twice daily is typically used in combination with antibiotics for 7 days. Tablets should be swallowed whole, with or without food, and must not be crushed or chewed. Administration in the morning is generally advised for once-daily dosing. Dosage adjustments may be necessary in patients with severe hepatic impairment.
Precautions
Patients should be advised to inform their healthcare provider of any liver disease or history of low magnesium levels. Long-term use of PPIs like Pariet has been associated with an increased risk of fractures, particularly of the hip, wrist, or spine, and low magnesium levels. Use of acid-suppressing medications may also increase the risk of gastrointestinal infections such as Clostridium difficile. Patients should be monitored periodically for adequacy of response and potential need for ongoing therapy.
Contraindications
Pariet is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or any component of the formulation. Concomitant use with rilpivirine-containing products is contraindicated due to the potential for decreased rilpivirine plasma concentrations and loss of virologic response. It should not be used in settings where rapid and complete acid suppression is not desired or may pose a risk.
Possible side effect
Common side effects may include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, and constipation. Less frequently, dizziness, rash, dry mouth, and elevated liver enzymes have been reported. Rare but serious adverse reactions include anaphylaxis, Stevens-Johnson syndrome, acute interstitial nephritis, and C. difficile-associated diarrhea. Patients should seek medical attention if they experience signs of an allergic reaction or severe gastrointestinal symptoms.
Drug interaction
Pariet may alter the absorption of drugs that are dependent on gastric pH for bioavailability, such as ketoconazole, iron salts, and digoxin. It can also affect the metabolism of drugs metabolized by CYP2C19, including warfarin, phenytoin, and diazepam. Concomitant use with methotrexate may increase methotrexate serum levels. Clinicians should review all concomitant medications and adjust doses as necessary.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed one is not recommended.
Overdose
There is limited experience with human overdose of rabeprazole. Reported doses of up to 80 mg have not described serious outcomes. In the event of suspected overdose, symptomatic and supportive care is recommended. Dialysis is not likely to be effective due to high protein binding of the drug.
Storage
Pariet tablets should be stored at room temperature (15–30°C or 59–86°F) in a dry place, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient needs and responses may vary.
Reviews
Clinical studies and post-marketing surveillance have consistently demonstrated the efficacy and tolerability of Pariet in diverse patient populations. It is regarded as a well-established option within the PPI class, with many clinicians noting its reliable acid suppression and favorable side effect profile. Patient-reported outcomes often highlight significant improvement in symptom control and quality of life, particularly in those with refractory GERD.